BIIB Stock Analysis: Biogen | NASDAQ
Drug Manufacturers - General | NASDAQ, USA | Market Cap: 32.824m USD | 12M Return: 50.9% | US09062X1037 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 242M
EPS Trend: -25.5%
Qual. Beats: 2
Rev. Trend: 32.3%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Biogen Inc. is a global biotechnology company that discovers, develops, manufactures, and commercializes therapies across neurology, immunology, and oncology. Its marketed portfolio includes multiple sclerosis treatments (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and the partnered OCREVUS), SPINRAZA for spinal muscular atrophy, SKYCLARYS for Friedreichs Ataxia, QALSODY for ALS, LEQEMBI for Alzheimers disease, ZURZUVAE for postpartum depression, and a range of oncology and autoimmune therapies (RITUXAN, GAZYVA, LUNSUMIO, glofitamab) developed in collaboration with Genentech/Roche. The company also markets biosimilars (BENEPALI, IMRALDI, FLIXABI) referencing major reference biologics such as Enbrel, Humira, and Remicade.
The business model is characterized by heavy reliance on strategic collaborations and licensing arrangements, with key partners including Eisai (LEQEMBI), Ionis Pharmaceuticals (SPINRAZA), Samsung Bioepis (biosimilars), Sage Therapeutics (ZURZUVAE), and Genentech. Biogen has expanded this external innovation model through newer agreements with Stoke Therapeutics (zorevunersen for Dravet syndrome), Dayra Therapeutics, Vanqua Bio, City Therapeutics (RNAi therapies), and ALTEOGEN (subcutaneous biologics formulations), which together underscore a pipeline strategy that combines internal R&D with in-licensed and partnered assets.
Geographically, the company sells its therapies in the United States, Europe, Germany, Asia, and other international markets. Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen is classified within the Health Care sectors Biotechnology sub-industry and operates as a large-cap NASDAQ-listed company.
- LEQEMBI Alzheimers launch drives long-term revenue growth
- MS franchise declines as TECFIDERA faces generic competition
- Cost restructuring program targets significant margin expansion
| Net Income: 835.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 2.70 > 1.0 |
| NWC/Revenue: 34.06% < 20% (prev 47.85%; Δ -13.79% < -1%) |
| CFO/TA 0.09 > 3% & CFO 2.88b > Net Income 835.1m |
| Net Debt (7.33b) to EBITDA (1.96b): 3.75 < 3 |
| Current Ratio: 1.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (148.7m) vs 12m ago 1.92% < -2% |
| Gross Margin: 67.71% > 18% (prev 72.53%; Δ -4.82% > 0.5%) |
| Asset Turnover: 32.93% > 50% (prev 35.29%; Δ -2.36% > 0%) |
| Interest Coverage Ratio: 3.91 > 6 (EBIT TTM 1.11b / Interest Expense TTM 284.8m) |
| A: 0.11 (Total Current Assets 7.31b - Total Current Liabilities 3.92b) / Total Assets 32.1b |
| B: 0.65 (Retained Earnings 21.0b / Total Assets 32.1b) |
| C: 0.04 (EBIT TTM 1.11b / Avg Total Assets 30.2b) |
| D: 1.42 (Book Value of Equity 18.8b / Total Liabilities 13.2b) |
| Altman-Z'' = 4.57 = AA |
| DSRI: 0.91 (Receivables 1.89b/2.08b, Revenue 9.95b/10.00b) |
| GMI: 1.07 (GM 72.53% / 67.71%) |
| AQI: 1.12 (AQ_t 0.67 / AQ_t-1 0.60) |
| SGI: 1.00 (Revenue 9.95b / 10.00b) |
| TATA: -0.06 (NI 835.1m - CFO 2.88b) / TA 32.1b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of October 12, 2026, the stock is trading at USD 225.71 with a total of 814,919 shares traded. Over the past week, the price has changed by +2.65%, over one month by +7.11%, over three months by +13.47% and over the past year by +50.87%.
Current recommended Stop Loss: 213.60 (which is 5.4% or 2.1 ATR below the current price).
Biogen has received a consensus analysts rating of 4.11. Therefore, it is recommended to buy BIIB.
- StrongBuy: 19
- Buy: 3
- Hold: 12
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 238.2 | 5.5% |
P/E Trailing = 39.4583
P/E Forward = 13.947
P/S = 3.2732
P/B = 1.7837
P/EG = 2.3453
Revenue TTM = 9.95b USD
EBIT TTM = 1.11b USD
EBITDA TTM = 1.96b USD
Long Term Debt = 7.29b USD (from longTermDebt, last quarter)
Short Term Debt = 800.0m USD (from shortTermDebt, last quarter)
Debt = 8.62b USD (from shortLongTermDebtTotal, last quarter) + Leases 264.8m
Net Debt = 7.33b USD (calculated: Debt 8.62b - CCE 1.28b)
Enterprise Value = 40.2b USD (32.8b + Debt 8.62b - CCE 1.28b)
Interest Coverage Ratio = 3.91 (Ebit TTM 1.11b / Interest Expense TTM 284.8m)
EV/FCF = 13.53x (Enterprise Value 40.2b / FCF TTM 2.97b)
FCF Yield = 7.39% (FCF TTM 2.97b / Enterprise Value 40.2b)
FCF Margin = 29.84% (FCF TTM 2.97b / Revenue TTM 9.95b)
Net Margin = 8.39% (Net Income TTM 835.1m / Revenue TTM 9.95b)
Gross Margin = 67.71% ((Revenue TTM 9.95b - Cost of Revenue TTM 3.21b) / Revenue TTM)
Gross Margin QoQ = 56.92% (prev 73.32%)
Tobins Q-Ratio = 1.25 (Enterprise Value 40.2b / Total Assets 32.1b)
Interest Expense / Debt = 3.30% (Interest Expense 284.8m / Debt 8.62b)
Taxrate = 2.49% (21.3m / 856.4m)
NOPAT = 1.09b (EBIT 1.11b * (1 - 2.49%))
Current Ratio = 1.87 (Total Current Assets 7.31b / Total Current Liabilities 3.92b)
Debt / Equity = 0.46 (Debt 8.62b / totalStockholderEquity, last quarter 18.8b)
Debt / EBITDA = 3.75 (Net Debt 7.33b / EBITDA 1.96b)
Debt / FCF = 2.47 (Net Debt 7.33b / FCF TTM 2.97b)
Total Stockholder Equity = 18.5b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.76% (Net Income 835.1m / Total Assets 32.1b)
RoE = 4.52% (Net Income TTM 835.1m / Total Stockholder Equity 18.5b)
RoCE = 4.32% (EBIT 1.11b / Capital Employed (Equity 18.5b + L.T.Debt 7.29b))
RoIC = 3.81% (NOPAT 1.09b / Invested Capital 28.5b)
WACC = 6.78% (E(32.8b)/V(41.4b) * Re(7.71%) + D(8.62b)/V(41.4b) * Rd(3.30%) * (1-Tc(0.02)))
Discount Rate = 7.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 84.09 | Cagr: 0.85%
[DCF] Terminal Value 77.97% ; FCFF base≈2.52b ; Y1≈2.89b ; Y5≈4.26b
[DCF] Fair Price = 384.0 (EV 64.1b - Net Debt 7.33b = Equity 56.7b / Shares 147.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -25.50 | EPS CAGR: -1.42% | SUE: 1.00 | # QB: 2
Revenue Correlation: 32.34 | Revenue CAGR: 0.52% | SUE: 2.38 | # QB: 2
EPS current Quarter (2026-09-30): EPS=2.04 | Chg30d=+0.30% | Revisions=-79% | Analysts=26
EPS current Year (2026-12-31): EPS=12.54 | Chg30d=-0.52% | Revisions=+0% | GrowthEPS=-17.9% | GrowthRev=+5.6%
EPS next Year (2027-12-31): EPS=16.54 | Chg30d=-0.03% | Revisions=+40% | GrowthEPS=+31.8% | GrowthRev=+2.0%
[Analyst] Revisions Ratio: -65% (up=3, down=20)